Table 1.
Clinicopathological features of the investigated study cohort.
| Clinicopathological Features | N (%) |
|---|---|
| Median age at initiation of RT (range) | 59 (29–83) |
| Gender | |
| Female | 10/33 (30.4%) |
| Male | 23/33 (69.6%) |
| Primary tumor | |
| Melanoma type | |
| Cutaneous | 28/33 (84.8%) |
| Ocular | 1/33 (3.0%) |
| Mucosal | 2/33 (6.1%) |
| Unknown primary site | 2/33 (6.1%) |
| Breslow depth 1 (median) | 2.2 mm |
| Clark-level 1 (median) | IV |
| BRAF mutated | 14/33 (42.4%) |
| Metastatic lesion | |
| Biopsy sites (N = 69) | |
| Lymph node (LN) | 24/69 (34.8%) |
| Skin and subcutaneous tissue | 29/69 (42.0%) |
| Lung | 3/69 (4.3%) |
| Central nervous system (CNS) | 6/69 (8.7%) |
| Liver | 1 (1.4%) |
| Gastrointestinal tract | 3 (4.3%) |
| Other (Bone, Palate mucosae, myocard) | 3 (4.3%) |
| Time between histological resection and IPI initiation (median) | 8 months |
| RPA class (median) | 2 |
| Quantitative data from immunofluorescence analysis | |
| % CD8+ CTL median (range) | 4 (1–37) |
| % GLUT-1high tumor cells median (range) | 42 (17–82) |
| % GLUT-1low tumor cells median (range) | 20 (2–58) |
| % CD73+ tumor cells median (range) | 7 (0–72) |
| Treatments | |
| Previous treatments | |
| Treatment-naïve | 3/33 (9.1%) |
| Previously treated | 30/33 (90.9%) |
| Treatment received | |
| Chemotherapy | 10/33 (30.3%) |
| Radiotherapy | |
|
14/33 (42.4%) 12/33 (36.3%) 7/33 (21.2%) |
| Ipilimumab | 33/33 (100%) |
| Anti-PD1/anti-PD-L1 inhibitors | 5/33 (15.1%) |
| BRAF ± MEK inhibitors | 8/33 (24.2%) |
| IPI prior to RT | 18/33 (54.5%) |
| Time between IPI initiation and RT (median) | 1 month |
| Follow-up | |
| Median survival upon RT (range) | 6 months (0–73 months) |
| Deceased | 29/33 (87.8%) |
1 Percentage based on the total number of patients with known Breslow’s depth (n = 25)/Clark-level (n = 19). Bold font indicates the subtitles in the table.